Short answer
Nuvation Bio Inc. (NUVB) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation), Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Additional capped calls executed July 1, 2026, tied to the Greenshoe Exercise.
Nuvation Bio Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Additional capped calls executed July 1, 2026, tied to the Greenshoe Exercise
- Designed to reduce potential Class A common-stock dilution upon convertible-note conversion
- Potential offset for cash payments exceeding converted-note principal
- Initial $10.4580 cap price, representing an 80.0% premium to June 25 NYSE closing price
Item 2.03 · Creation of a Direct Financial Obligation
- Total convertible debt increased to $287.5M, including the fully exercised $37.5M greenshoe option
- 0.75% annual interest, semiannual payments beginning January 1, 2027, with maturity on July 1, 2032
- Estimated net proceeds of $277.6M, expanding funding for working capital, operating expenses, capital expenditures, and general corporate needs
- Approximately $2.2M of proceeds funded additional capped call transactions, potentially reducing conversion-related dilution
- General unsecured obligations convertible into cash, Class A shares, or a combination at Nuvation Bio’s election
Item 8.01 · Other Events
- Forward-looking statements concern Nuvation Bio’s planned use of remaining net proceeds from its offering
- Plans remain subject to market conditions, trends, and other risks identified in the company’s SEC filings
- Investors should assess execution risk against the Risk Factors in the quarter ended March 31, 2026 Form 10-Q
Item EX-99.1 · Exhibit EX-99.1
- Greenshoe fully exercised, increasing convertible notes offering to $287.5 million
- Notes carry 0.75% interest and mature in 2032, adding low-cost long-term financing
- Estimated net proceeds approximately $277.6 million after underwriting discounts and offering expenses
- Additional capped calls cost approximately $2.2 million, with an $10.4580 cap price
- Remaining proceeds earmarked for working capital, operating expenses, capital expenditures and general corporate purposes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvation Bio Inc. 8-K filings
Get the next NUVB 8-K as it lands
Follow NUVB for push alerts, or ask the research agent what this filing means.